Meeting
2019 ASCO Annual Meeting
Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.
Authors
Wolfgang Wick
National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany
Wolfgang Wick , Tobias Kessler , Michael Platten , Christoph Meisner , Michael Bamberg , Ulrich Herrlinger , Caroline Happold , Sarah Weisang , Hanna Boelting , Joachim Steinbach , Guido Reifenberger , Felix Sahm , Andreas von Deimling , Antje Wick , Michael Weller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2013)
DOI
10.1200/JCO.2019.37.15_suppl.2013
Abstract #
2013
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiotherapy with capecitabine with or without temozolomide in patients with locally advanced rectal cancer: A prospective, randomized phase 2 study stratified by MGMT (O6-methylguanine DNA methyltransferase) status: KCSG-CO17-02.
First Author: Chung Ryul Oh
Poster
2014 ASCO Annual Meeting
MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide.
First Author: Riccardo Soffietti
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2019 ASCO Annual Meeting
Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment.
First Author: Christopher Ray Trevino